Author:
Demirci Umut,Tufan Gulnihal,Aktas Bilge,Balakan Ozan,Alacacioglu Ahmet,Dane Faysal,Engin Huseyin,Kaplan M. Ali,Gunaydin Yusuf,Ozdemir Nuriye Y.,Tugba Unek I.,Karaca Halit,Akman Tulay,Sonmez Ozlem U.,Coskun Ugur,Harputluoglu Hakan,Sevinc Alper,Tonyali Onder,Buyukberber Suleyman,Benekli Mustafa
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference31 articles.
1. Bokstein F, Shpigel S, Blumenthal DT (2008) Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 112:2267–2273
2. Brandes AA, Tosoni A, Amistà P, Nicolardi L, Grosso D, Berti F et al (2004) How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology 63:1281–1284
3. Buckner JC (2003) Factors influencing survival in high-grade gliomas. Semin Oncol 30:10–14
4. Cancer Therapy Evaluation Program. Common Terminology Criteria For Adverse Events, version 3, 9 Aug (2006). http://ctepcancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf . Accessed 15 Oct, 2012
5. Demirci U, Yaman M, Buyukberber S, Coskun U, Baykara M, Uslu K et al (2012) Prognostic importance of markers for inflammation, angiogenesis and apoptosis in high grade glial tumors during temozolomide and radiotherapy. Int Immunopharmacol 14:546–549
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献